Site icon pharmaceutical daily

Dementia – Pipeline Review, H1 2019 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Dementia
– Pipeline Review, H1 2019”
drug pipelines has been added to ResearchAndMarkets.com’s
offering.

Dementia – Pipeline Review, H1 2019 provides
comprehensive information on the therapeutics under development for
Dementia (Central Nervous System), complete with analysis by stage of
development, drug target, mechanism of action (MoA), route of
administration (RoA) and molecule type.

The guide covers the descriptive pharmacological action of the
therapeutics, its complete research and development history and latest
news and press releases.

The Dementia (Central Nervous System) pipeline guide also reviews of key
players involved in therapeutic development for Dementia and features
dormant and discontinued projects.

The guide covers therapeutics under Development by Companies
/Universities /Institutes, the molecules developed by Companies in Phase
III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 5,
17, 20, 48, 17 and 3 respectively.

Similarly, the Universities portfolio in Phase I, Preclinical and
Discovery stages comprises 1, 10 and 3 molecules, respectively.

Dementia (Central Nervous System) pipeline guide helps in identifying
and tracking emerging players in the market and their portfolios,
enhances decision making capabilities and helps to create effective
counter strategies to gain competitive advantage.

Scope:

Topics Covered

  1. Introduction
  2. Dementia – Overview
  3. Dementia – Therapeutics Development
  4. Dementia – Therapeutics Assessment
  5. Dementia – Companies Involved in Therapeutics Development
  6. Dementia – Drug Profiles
  7. Dementia – Dormant Projects
  8. Dementia – Discontinued Products
  9. Dementia – Product Development Milestones

Companies Mentioned

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/q68lkb/dementia?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Central
Nervous System Drugs

Exit mobile version